Shares of Labcorp Holdings Inc (LH) are surging 5.23% in pre-market trading on Thursday following the company's release of impressive second-quarter results and an upward revision of its full-year 2025 guidance.

The diagnostic testing and drug development company reported Q2 adjusted earnings per share of $4.35, significantly beating the analyst consensus estimate of $4.17. Revenue for the quarter came in at $3.53 billion, surpassing Wall Street expectations of $3.49 billion. Both figures showed substantial year-over-year growth, with adjusted EPS rising from $3.94 and revenue increasing from $3.22 billion in the same quarter last year.

In light of the strong performance, Labcorp has raised its full-year 2025 outlook. The company now expects adjusted earnings per share between $16.05 and $16.50, up from its previous guidance of $15.70 to $16.40. The midpoint of this new range is notably higher than the FactSet analyst consensus of $16.07. Additionally, Labcorp revised its revenue growth forecast to 7.5% - 8.6%, up from the previous 6.7% - 8% range. The company cited robust demand for its diagnostic tests and the underlying strength of its businesses as key drivers for the improved outlook. Investors are reacting positively to these developments, as reflected in the stock's pre-market surge.